tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioAtla (BCAB), IVERIC bio (ISEE) and Acelrx (ACRX)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAtla (BCABResearch Report), IVERIC bio (ISEEResearch Report) and Acelrx (ACRXResearch Report).

BioAtla (BCAB)

H.C. Wainwright analyst Arthur He CFA reiterated a Buy rating on BioAtla today and set a price target of $25.00. The company’s shares closed last Wednesday at $4.08, close to its 52-week low of $3.40.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioAtla with a $32.25 average price target.

See today’s best-performing stocks on TipRanks >>

IVERIC bio (ISEE)

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on IVERIC bio, with a price target of $26.00. The company’s shares closed last Wednesday at $14.95.

Caufield has an average return of 19.5% when recommending IVERIC bio.

According to TipRanks.com, Caufield is ranked #6627 out of 7897 analysts.

IVERIC bio has an analyst consensus of Strong Buy, with a price target consensus of $25.83, an 80.1% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $28.00 price target.

Acelrx (ACRX)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Acelrx today. The company’s shares closed last Wednesday at $0.22, close to its 52-week low of $0.22.

According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.6% and a 36.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Acelrx.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BCAB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More